II. Indications
III. Mechanism
- See Acetylcholinesterase Inhibitor
- Carbamate-based noncompetitive Cholinesterase Inhibitor
- Inhibits butyrylcholinesterase and acetylcholinesterase
- Increases Cholinergic transmission
IV. Pharmacokinetics: Oral Route
- Peak: 1 hour
- Duration: 10 hours
V. Drug Interactions
- No significant Drug Interactions
VI. Efficacy
- Modestly improves scores on Neuropsychological Tests
- Benefits decrease after 40 weeks of treatment
VII. Adverse Effects
- See Acetylcholinesterase Inhibitor
- Specific adverse effects reported for Rivastigmine, not seen with other Acetylcholinesterase Inhibitors
VIII. Dosing
- Oral Route
- Initial: 1.5 mg orally twice daily with food for at least 2 weeks (4 weeks for Lewy Body Dementia)
- Next: 3 mg orally twice daily with food for at least 2 weeks (4 weeks for Lewy Body Dementia)
- Next: 4.5 mg orally twice daily with food for at least 2 weeks (4 weeks for Lewy Body Dementia)
- Next: 6 mg orally twice daily with food
- Transdermal Patch
- Initial: 4.6 mg patch every 24 hours for at least 4 weeks
- Next: 9.5 mg patch every 24 hours for at least 4 weeks
- Next: 13.3 mg patch every 24 hours
Images: Related links to external sites (from Bing)
Related Studies (from Trip Database) Open in New Window
| rivastigmine (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| RIVASTIGMINE 1.5 MG CAPSULE | Generic | $0.99 each |
| RIVASTIGMINE 13.3 MG/24HR PTCH | Generic | $7.45 each |
| RIVASTIGMINE 3 MG CAPSULE | Generic | $1.00 each |
| RIVASTIGMINE 4.5 MG CAPSULE | Generic | $0.93 each |
| RIVASTIGMINE 4.6 MG/24HR PATCH | Generic | $7.53 each |
| RIVASTIGMINE 6 MG CAPSULE | Generic | $0.88 each |
| RIVASTIGMINE 9.5 MG/24HR PATCH | Generic | $7.35 each |
| exelon (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| EXELON 13.3 MG/24HR PATCH | Generic | $7.45 each |
| EXELON 4.6 MG/24HR PATCH | Generic | $7.53 each |
| EXELON 9.5 MG/24HR PATCH | Generic | $7.35 each |
Ontology: rivastigmine (C0649350)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C072506 |
| SnomedCT | 323368009, 395868008 |
| English | (S)-N-ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate, Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1), rivastigmine, rivastigmine (medication), RIVASTIGMINE, rivastigmine [Chemical/Ingredient], Rivastigmine, Rivastigmine (product), Rivastigmine (substance) |
| Spanish | rivastigmina (producto), rivastigmina (sustancia), rivastigmina |
Ontology: Exelon (C0730987)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C072506 |
| English | Exelon, rivastigmine (Exelon), exelon |
